| This week's sponsor is FierceBiotech Executive Breakfast at BIO 2018. | | | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. Publisher’s Note: In preparation for the new GDPR taking effect this month, we would like to reconfirm your subscription to our newsletter(s). Please click this link to reconfirm your subscription. For more information about GDPR, please visit this page. | |
|
Featured Story | | | Tuesday, May 15, 2018 In many ways, 2017 was a “wait-and-see” year for biopharma as a new administration entered the White House. The industry came under fire early when President-elect Donald Trump said it was “getting away with murder” on pricing. More than a year later, biopharma has been spared real reform, and that’s reflected in overall revenues. Which pharma companies wound up on top? |
|
|
| This week's sponsor is Qualicaps. | | | [Webinar] Capsule-Based DPIs - Understanding the Science
May 22, 2018 | 4pm CET / 10am EDT
This webinar will discuss several capsule formulations used in DPIs and will compare their performance. It will provide an overview on some of the novel methods being employed to evaluate the physical characteristics and mechanical properties of capsules, and will also address the factors influencing the aerosolisation performance of different capsule types. Register Now |
Top Stories Of The Week Wednesday, May 16, 2018 Two people signed Novartis' infamous contract with Michael Cohen, and now they've both left. One was ex-CEO Joe Jimenez, who has his own take on the $1.2 million contract that landed Novartis in its biggest scandal yet. The other? General Counsel Felix Ehrat, who took "personal responsibility" and quit as of June 1. Tuesday, May 15, 2018 Just a few weeks out from ASCO, and with more than a touch of inevitability, Roche is axing its IDO/TDO inhibitor work “in its entirety” with partner NewLink Genetics as the fallout from a string of weak IDO trials across biopharma continues. Tuesday, May 15, 2018 As Novartis' $1.2 million contract with President Donald Trump’s personal lawyer Michael Cohen draws scrutiny from law enforcement in Switzerland and lawmakers in the U.S., CEO Vas Narasimhan got on the phone with 5,000 top managers for a pep talk about following the rules. Monday, May 14, 2018 Looking back on the past 25 years, old stalwarts Lipitor and Plavix and a trio of autoimmune TNF-alpha inhibitors are among the best-selling drugs in the U.S. We expect you'll guess which drug is set to take the crown next. Thursday, May 17, 2018 Shares in Jounce Therapeutics plummeted upon the publication of an abstract for a phase 1/2 trial of its first-in-class ICOS inhibitor JTX-2011, although the company says the drug showed evidence of efficacy. Monday, May 14, 2018 The problem with the common cold is that it’s caused by many viruses that evolve so quickly they can't be attacked with antiviral medications or vaccines. Now, researchers at Imperial College London believe they’ve found a molecule that can block multiple strains of the cold by targeting a protein the virus needs to survive. Monday, May 14, 2018 Betting heavily on a less-regulated CMO market, a Chinese company intends to build a massive biologics plant over the next several years to tap into what it predicts will be the country’s rapid move to cell-based drugs. Friday, May 11, 2018 Investigators from the Mayo Clinic and AliveCor demonstrated that a trained artificial intelligence network can help identify people at increased risk of arrhythmias and sudden cardiac death despite displaying a normal heart rhythm on their electrocardiogram. Tuesday, May 15, 2018 VBI wants to prevent cytomegalovirus infections in newborns by vaccinating women before pregnancy. And they just got backing from positive early-stage clinical data on a vaccine that aims to do just that. Tuesday, May 15, 2018 MD Anderson Cancer Center detailed the successes of their collaborative clinical research model, which directly connects academic experts to big pharma studies through a leukemia pilot program allowing for multiple, simultaneous immunotherapy studies. | This week's sponsor is Life Science Women's Conference. | | | |
Resources Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: Veeva Systems Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams. Sponsored by: Veeva Systems To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights. Sponsored by: Veeva Systems Explore a new model for events management, and learn how to deliver more value. Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. |
